Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CNSI-Fe and Radiotherapy in Solid Tumors
NCT07491783Phase 2Not yet recruiting
- Sponsor
- Sichuan Enray Pharmaceutical Sciences Company
- Start
- Mar 2026
- Primary completion
- Dec 2027
- Modality
- Nanoparticles
- Countries
- 1
01
Overview
A Phase 2 trial of CNSI-Fe in solid tumor, head and neck squamous cell carcinoma (HNSCC), soft tissue sarcoma (STS), sponsored by Sichuan Enray Pharmaceutical Sciences Company. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
CNSI-Fe
03
Conditions
solid tumorhead and neck squamous cell carcinoma (HNSCC)soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT07491783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07491783.